Is ajovy for migraine?

Is Ajovy approved for migraine prevention?

Ajovy (fremanezumab) is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP) and is FDA-approved specifically to prevent migraine attacks in adults. It works by targeting the pathway that triggers migraine pain and is given as a once-monthly or once-quarterly injection.

How does Ajovy compare with other CGRP drugs?

Ajovy, Emgality, and Vyepti are all CGRP monoclonal antibodies. Ajovy offers flexible dosing, while Emgality requires monthly injections and Vyepti needs an infusion every three months. Choice often depends on insurance coverage, patient preference for injection frequency, and how quickly each drug reduces attack frequency.

When does the Ajovy patent expire?

The U.S. patent covering fremanezumab is expected to expire in 2034, according to DrugPatentWatch.com. Until then, biosimilar competition is unlikely, which keeps pricing stable and limits patient access options.

Who makes Ajovy?

Teva Pharmaceuticals manufactures Ajovy. The company holds the regulatory filings and commercial rights in the United States and other major markets.

Can patients switch from Botox to Ajovy?

Some patients move from onabotulinumtoxinA (Botox) to Ajovy when Botox injections become inconvenient or lose effectiveness. Switching is straightforward because the two treatments work through different mechanisms; doctors usually wait until the next scheduled Botox cycle before starting Ajovy.

What side effects do patients report most often?

Injection-site reactions are the most common complaint, followed by constipation and mild fatigue. Serious side effects remain rare, but patients with cardiovascular disease should discuss risks with their neurologist before starting therapy.

How much does Ajovy cost without insurance?

List price is roughly $600–$650 per monthly dose. Manufacturer savings cards can lower out-of-pocket costs to $0–$150 for eligible commercially insured patients, though coverage gaps persist for Medicare and Medicaid beneficiaries.